MSC2360844 hemifumarate
- CAS No.
- 1621688-31-0
- Chemical Name:
- MSC2360844 hemifumarate
- Synonyms
- MSC2360844 hemifumarate;Roginolisib (IOA-244) hemifumarate
- CBNumber:
- CB39630625
- Molecular Formula:
- C30H31FN4O9S
- Molecular Weight:
- 642.66
- MDL Number:
- MOL File:
- 1621688-31-0.mol
| form | Solid |
|---|---|
| color | White to off-white |
| FDA UNII | W8JCY5F7F3 |
MSC2360844 hemifumarate Chemical Properties,Uses,Production
Uses
Roginolisib (MSC2360844) hemifumarate is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib hemifumarate shows highly selective against a panel of 278 additional kinases[1].
in vivo
Roginolisib hemifumarate (6.6-66 mg/kg; daily from week 2 to 10) ameliorates disease manifestations in a murine SLE model[1].
| Animal Model: | NZB/W F1 female mice[1] |
| Dosage: | 6.6, 22, or 66?mg/kg |
| Administration: | Oral; starting at week 2 post ADV-IFNα delivery, once daily at 10?weeks |
| Result: | Significantly reduced proteinuria incidence and severity in a dose-dependent manner. |
IC 50
PI3Kδ: 145 nM (IC50)
References
[1] Haselmayer P, et al. Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies. Front Immunol. 2014 May 22;5:233. DOI:10.3389/fimmu.2014.00233
MSC2360844 hemifumarate Preparation Products And Raw materials
Raw materials
Preparation Products
MSC2360844 hemifumarate Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | 4008200310 | marketing@tsbiochem.com | China | 24961 | 58 |
| Nantong QuanYi Biotechnology Co., Ltd | 0513-66337626 18051384581 | sales@chemhifuture.com | China | 5929 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11973 | 58 |
| RD International Technology Co., Limited | 18024082417 | market@ubiochem.com | China | 9835 | 58 |
| Shanghai Fine Biotech Co.,Ltd | 18221172427 | sale@fine-biotech.com | China | 2741 | 58 |




